EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative analysis of mortality patterns and treatment strategies in thalassaemia and sickle cell disease patients: A 12‐year study

Sophia Delicou iD, Konstantinos Manganas iD, Michael D Diamantidis iD, Theodora Maria Venou, Polyxeni Delaporta, Despoina Pantelidou, Eirini Spachiou, Sofia Tsagia, Vasiliki Pappi, Foteini Petropoulou, Eleni Kapsali, Loukia Evliati und 21 weitere

British Journal of Haematology · 2025-05 · 206 (5) · 1466-1478

DOI: 10.1111/bjh.20043 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift British Journal of Haematology, online erschienen am 16.03.2025. Verfasst von Sophia Delicou und 32 weiteren Autor:innen. Beteiligte Einrichtung: Hippokrateio General Hospital, Thalassaemia and Sickle Cell Disease Unit, Expertise Center of Haemoglobinopathies and Their Complications, Athens, Gr…. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Thalassemia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study examined mortality rates among 2475 patients with thalassaemia and sickle cell disease (SCD) per year over 12 years in Greece, recording 335 deaths (27.92/year), with an overall mortality rate of 1.13% per year. The primary aim was to identify causes of death, comorbidities, treatment efficacy and iron overload prevalence. Of the deaths, 239 were attributed to thalassaemia and 96 to SCD. For thalassaemia patients, cardiac failure, hepatocellular carcinoma and sepsis were the leading causes of death, with no neoplasms observed in β+/β+ genotypes. In SCD, sepsis, liver failure and stroke were the predominant causes, with sepsis‐related deaths higher in frequently transfused patients. The median age of death was significantly lower in thalassaemia (50 years) compared to SCD (58.49 years, p < 0.001). Differences in comorbidities and treatment effectiveness highlight the need for improved management strategies. Addressing iron overload, optimizing chelation therapy and expanding hydroxyurea use in SCD patients could enhance survival and quality of life. Strengthening treatment protocols and monitoring may reduce mortality, emphasizing the importance of targeted interventions in haemoglobinopathies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellThalassemiaHumansMaleFemaleMiddle AgedAdultAgedIron OverloadYoung AdultGreeceAdolescentChildCause of DeathComorbidityHydroxyurea

Stichwörter der Autor:innen

haemoglobinopathiesmortality causesmortality ratespredisposing factorssickle cell diseasethalassaemia

Substanzen

Hydroxyurea

Autor:innen und Institutionen

  • Hippokrateio General Hospital, Thalassaemia and Sickle Cell Disease Unit, Expertise Center of Haemoglobinopathies and Their Complications, Athens, Greece.
  • Thalassemia and Sickle Cell Disease Unit, Department of Hematology, General Hospital of Larissa, Larissa, Greece.
  • Hippokrateio General Hospital, Adult Thalassaemia Unit, Thessaloniki, Greece.
  • Thalassemia Unit, First Department of Pediatrics, National and Kapodistrian University of Athens, Athens, Greece.
  • Aghia Sophia' Children's Hospital, ERN-EuroBloodNet Center, Athens, Greece.
  • AHEPA University Hospital, Thalassaemia and Sickle Cell Unit, Thessaloniki, Greece.

ORCID-Profile: Sophia Delicou, Konstantinos Manganas, Michael D Diamantidis, Antonis Kattamis

Zitieren

APA

Delicou, S., Manganas, K., Diamantidis, M. D., Venou, T. M., Delaporta, P., Pantelidou, D., Spachiou, E., Tsagia, S., Pappi, V., Petropoulou, F., Kapsali, E., Evliati, L., Papaioannou, K., Katsatou, M., Klironomos, E., Vasiliadi, A., Gkoutzouvelidis, A., Giasari, P., Zisis, C., …, & Vlachaki, E. (2025). Comparative analysis of mortality patterns and treatment strategies in thalassaemia and sickle cell disease patients: A 12‐year study. British Journal of Haematology, 206(5), 1466-1478. https://doi.org/10.1111/bjh.20043

Vancouver

Delicou S, Manganas K, Diamantidis MD, Venou TM, Delaporta P, Pantelidou D, et al. Comparative analysis of mortality patterns and treatment strategies in thalassaemia and sickle cell disease patients: A 12‐year study. British Journal of Haematology. 2025;206(5):1466-1478. doi:10.1111/bjh.20043

BibTeX
@article{Delicou2025,
  author = {Delicou, Sophia and Manganas, Konstantinos and Diamantidis, Michael D and Venou, Theodora Maria and Delaporta, Polyxeni and Pantelidou, Despoina and Spachiou, Eirini and Tsagia, Sofia and Pappi, Vasiliki and Petropoulou, Foteini and Kapsali, Eleni and Evliati, Loukia and Papaioannou, Konstantina and Katsatou, Marianna and Klironomos, Evangelos and Vasiliadi, Artemis and Gkoutzouvelidis, Angelos and Giasari, Panagiota and Zisis, Christos and Lafiatis, Ioannis and Goula, Anastasia and Xydaki, Aikaterini and Papadopoulou, Despina and Chatzoulis, Christos and Lafioniatis, Stylianos and Vini, Dimitra and Serpanou, Anastasia and Kalkana, Chrysoula and Kyriakaki, Stavroula and Drandaki, Maria and Kouraklis, Alexandra and Kattamis, Antonis and Vlachaki, Efthymia},
  title = {Comparative analysis of mortality patterns and treatment strategies in thalassaemia and sickle cell disease patients: A 12‐year study},
  journal = {British Journal of Haematology},
  year = {2025},
  volume = {206},
  number = {5},
  pages = {1466--1478},
  doi = {10.1111/bjh.20043}
}
Kostenlos starten →